Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACRS vs SGMO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–4 Matrix Metrics)

SGMO Overall Winner 6-Pillar Tally: ACRS 0 – 5 SGMO (1 Tie) Matrix Metrics: ACRS 4 – 5 SGMO

As of Nov 16, 2026, Sangamo Therapeutics, Inc. (SGMO) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACRS carries a Unified Composite Score of 38.7/100 (SELL) at $3.65 (N/M Forward P/E, -1412.4% operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin).

  • Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACRS vs SGMO
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.65
-7.02% 1D
Market Cap $620.2M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.53β · 73% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 50.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.9%), weak momentum, RSI 41
RSI-14: 40.5 · SMA20: $3.88 · SMA50: $4.38
SGMO NASDAQ Head-to-Head Winner
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31

6-Pillar Scorecard Institutional Category Breakdown (ACRS 0 – 5 SGMO)

Columns: Metric · ACRS · SGMO
1. Valuation Multiples SGMO
Forward P/E N/M 0.4x
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue 96.9x 1.2x
2. Growth & Scale SGMO
Revenue Growth (YoY) -55.1% +88.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.4M $40M
Market Cap $620.2M $55.9M
3. Profitability & Quality SGMO
Gross Margin N/A N/A
Operating Margin -1412.4% -175.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.5% -2891.8%
4. Balance Sheet & Cash Flow SGMO
Cash Generation (TTM) -$75M -$90M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.11 Book/Sh · -55.5% ROE $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 60.7% (1st %ile) 144.2% (71st %ile)
Put/Call OI Skew 8.77x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACRS (4) vs SGMO (5)
Institutional Metric ACRS SGMO Criterion Row Edge
Market Capitalization
Scale
$620.2M $55.9M Larger Scale ACRS
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY)
Growth
-55.1% +88.4% Higher Growth SGMO
Operating Margin (TTM)
Profitability
-1412.4% -175.5% Higher Margin SGMO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.5% -2891.8% Higher ROE ACRS
52-Week Range Position
Momentum
32% ($2–$7) 9% ($0–$1) Stronger Trend ACRS
Beta / 30D Volatility
Risk Regime
1.53β · 73% Vol 1.49β · 206% Vol Lower Realized Risk ACRS
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 52.0 / 100 (HOLD) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
$6.4M $40M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 96.9x EV/Rev N/M PEG · 1.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($1.11 Book/Sh · -55.5% ROE) -$90M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACRS +48.68 pp
ACRS: +7.86% · SGMO: -40.82%
3M Horizon ACRS +94.39 pp
ACRS: +25.66% · SGMO: -68.73%
6M Horizon ACRS +155.72 pp
ACRS: +95.26% · SGMO: -60.46%
1Y Horizon ACRS +155.72 pp
ACRS: +95.26% · SGMO: -60.46%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACRS Revenue SGMO Revenue ACRS Op. Margin SGMO Op. Margin Margin Leader
Q3 '25 $10M $0M -516.8% -6119.3% ACRS
Q4 '25 $10M $60M -1724.6% -175.5% SGMO
Q1 '26 $10M $10M -1111.8% -2215.4% ACRS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACRS BREAKDOWN
129d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew 8.77x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $620.2M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACRS vs SGMO Key Questions & Quantitative Answers

As of Nov 16, 2026, Sangamo Therapeutics, Inc. (SGMO) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACRS carries a Unified Composite Score of 38.7/100 (SELL) at $3.65 (N/M Forward P/E, -1412.4% operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin). Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMO leads the Growth & Scale pillar: ACRS posts -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). Across the 3-period historical trajectory (Q3 '25 to Q1 '26), ACRS cumulative revenue shifted +0.0% while SGMO shifted -83.3%. In operating R&D and SG&A reinvestment, ACRS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.

SGMO screens cheaper on headline valuation multiples. ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 96.9x EV/Revenue (unreported FCF margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACRS (-55.5% ROE) versus SGMO (-2891.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), a 8.77x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.53β · 73% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.